47results about "Tissue screening" patented technology

The present disclosure provides methods of making tissue-derived epithelial organoids. In particular, the present disclosure provides a tissue-derived epithelial organoid embedded in a hydrogel suspended in a culture medium. The present disclosure further provides methods of using such organoids.

This method for producing a brain organoid including aggregated tau protein comprises: a step (a) for culturing pluripotent stem cells in the presence of SMAD inhibitor to form embryoid bodies; a step (b) for embedding the embryoid bodies in an extracellular matrix and three-dimensionally culturing the embryoid bodies in the presence of SMAD inhibitor and GSK3β inhibitor to form an organoid that includes neural precursor cells; a step (c) for removing the organoid from the extracellular matrix and suspension-culturing the organoid in the presence of LIF to form a brain organoid; a step (d) for forcing the brain organoid to express a modified MAPT gene; and a step (e) for further suspension-culturing the brain organoid after step (d) to obtain a brain organoid having an aggregated tau protein.

The field of the invention is in vitro assays for the production of in vitro organ culture systems and the use of such in vitro organ culture systems for screening assays in drug screening, patient selection and personalized medical context. More specifically, the present invention relates to an in vitro method of establishing a tumor organoid from a cancer tissue sample obtained from a subject, an in vitro method of providing immune cells activated by an autologous tumor organoid, a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject, and a method of preparing an in vitro organ culture system for mimicking interaction of a tumor with an immune system of a subject. The invention relates to an in vitro organ culture system, and to an in vitro organ culture system produced thereby, to a method for determining the reactivity of a tumor to at least one immunooncology drug therapy using said in vitro organ culture system, and to a kit for preparing an in vitro organ culture system that mimics the interaction of a tumor with the immune system of a subject, as disclosed herein.

The present invention discloses, in one embodiment, a method of using human induced pluripotent stem cells to generate three-dimensional human organ tissue for therapeutic drug toxicity and discovery⋅. In one embodiment, a high throughput microtiter plate is loaded with both wild type and Rett disease 3D spheroids and exposed to a drug library, and activity is measured and analyzed for disease rescue to wild type cell behavior.

The present disclosure is directed to methods of producing a predictive model or human avatars for assessing Central Nervous System (CNS) disorders using organoids, optionally with artificial intelligence (Al).

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

The present invention relates to a three-dimensional organotypic skin model of hydrogel comprising: - an epidermis of human keratinocytes; - a dermis of human fibroblasts; and - immune cells derived from human induced pluripotent stem cells.

The present invention relates to purified biocompatible mucus capable of forming a gel. The mucus of the present invention may be provided in a tissue model along with a cell population. The mucin or tissue model of the present invention may be useful in in vitro models of digestion, mucus penetration, and / or epithelial transport.

It is provided a protocol to induce the formation of lower respiratory tract organoids in only 21 days, the organoids containing markers of both proximal and distal regions. The organoids is obtained by leveraging cellular interactions between airway bronchial epithelial cells and fibroblasts. It is also provided the use of the organoids to study respiratory viral infections with strong similarity to adult lung tissue.

Organ-on-chip system, including a bio-engineered lung region that is functionally connected to a bio-engineered lymphatic region via a functionalized connection region. The bio-engineered lung region includes cultured or transplanted lung cells / tissue, which can mimic in vivo lung function, and the bio-engineered lymphatic region includes lymphatic cells / tissue, which can mimic in vivo lymphatic function. The connection region allows for stimuli and cell secretions to be transported between the lung region and the lymphatic region to confer immune competency to the lung region, as the lymphatic region can generate an immune response based on stimuli received from the lung region, for example, in response to infections or therapeutic agents

The present invention provides methods for engrafting a bone marrow organoid with CD34+ hematopoietic stem and progenitor cells. Compositions comprising the factors needed for engraftment are also provided.

Three-dimensional tumor avatars comprising an artificial scaffold, tumor cells, tumor associated endothelial cells and tumor associated fibroblast cells are provided. Kits comprising the 3D tumor avatars, methods of producing the 3D tumor avatars and methods of using the 3D tumor avatars are also provided.

The invention relates to a skin injury organ model and a method for screening drugs by using the skin injury organ model, and the skin injury organ model is characterized in that skin cells, accessory structures, nerve cells, fat cells and the like form structures similar to actual skin by using an air-liquid interface skin organ preparation technology; and the damaged skin is prepared by irradiating the skin-like organ with ultraviolet rays which actually reach the ground surface. In the present invention, the skin barrier is damaged and the activity of a matrix proteolytic enzyme is improved to promote the decomposition of collagen while increasing the secretion of pro-inflammatory cytokines by irradiating with solar-simulated ultraviolet light comprising 94.5% ultraviolet light (UV-A) and 5.5% ultraviolet light (UV-B), thereby well simulating the characteristics of skin injury caused by ultraviolet light. Therefore, the invention can be used as a model of skin injury and photoaging caused by ultraviolet rays, and can be useful in potential therapeutic drug screening.

We provide a treatment for atopic dermatitis. [Solution] A use is provided for manufacturing a pharmaceutical composition for the prevention or treatment of atopic dermatitis, comprising Cutibacterium acnes or its culture medium as an active ingredient.

The invention relates to a method of generating endolymph-producing epithelial cells and in vitro use of a hedgehog signalling inhibitor for differentiation of inner ear progenitor cells into endolymph-producing epithelial cells; in vitro endolymph-producing epithelial cells and an inner ear organoid comprising endolymph-producing epithelial cells. Also provided is in vitro use of an inner ear organoid in drug discovery; the endolymph-roducing epithelial cells for use in a method of treating diseases of the inner ear; and a method of testing one of more therapeutic agents using these cells or organoids. Lastly, also provided is a kit and an organoid maturation medium.

The application discloses a kind of 3D cutin layer model construction method and its application, the 3D cutin layer model is constituted by top surface, middle layer and bottom surface, top surface and bottom surface surface are uneven, are constituted by apoptosis cell and / or cell derivative that are closely connected with photocurable gel, middle layer is photocurable gel, wherein photocurable gel is as the skeleton for apoptosis cell and / or cell derivative provides pore structure.The construction method is to load apoptosis keratinocyte and / or cell derivative in the condition of light irradiation with photocurable gel material and form 3D cutin layer model.The 3D cutin layer model constructed by the application can be effectively applied to in vitro evaluation of the efficacy of cosmetic regulation microecology, test the efficacy of antibiotic biological preparation such as bacteriostatic, with the advantages of low cost, fast construction speed, high stability and high-throughput screening of active substances.

Disclosed herein are systems and methods for testing effects of simulated microgravity on muscle structures. The system includes a clinostat and an adapter that is receivable into the clinostat. The adapter includes a housing that defines at least one receptacle. The system further includes an assembly having a substrate and a plurality of fibrils deposited on the substrate. The plurality of fibrils comprise collagen and extend along an axis. The assembly is receivable into a first receptacle of the at least one receptacle. The plurality of fibrils can have myoblasts thereon. Operation of the clinostat simulates microgravity. Test substances can screened using the muscle structures to determine effects on myogenesis.

An anticancer drug assessment method including the steps of: culturing a cell structure containing stromal cells in which a gene encoding a live cell marker protein has been knocked out and cancer cells in the presence of an anticancer drug; and assessing the anticancer drug using an expression level of the live cell marker protein as an index in this order, wherein in the assessment, the expression level of the live cell marker protein is measured using a culture supernatant, or in the assessment, a substance that fluoresces or produces color when reacted with the live cell marker protein is added, and the expression level of the live cell marker protein is measured based on the amount of fluorescence or coloration of the substance.

An in-vitro tissue model for use with a test article includes a tissue sample that includes homogeneous tuna meat having an isotropic thermal response, wherein the tuna meat is characterized by a plurality of visually distinct color states, each color state corresponding to a respective temperature to which the tuna meat has been heated within a range of 43° C. to 60° C., thereby providing a visual indication of the thermal effect of the test article within said range.

A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGF1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i) to iii): i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-β (TGF-β) inhibitor.

A cell culture device and associated method for preparing an in vitro model of a neuromuscular junction (NMJ) is provided. The cell culture device has a cell culture layer (22) including a neuronal channel for receiving neuronal cells therein and a neuromuscular junction chamber in fluid communication with the neuronal channel for receiving muscle cells therein to allow co-culture of neuronal and muscle cells and form an NMJ. The neuronal channel includes a first portion having a first partial cross-section and a second portion downstream of the first portion for holding neuronal cells and having a second partial cross-section smaller than the first partial cross-section. The neuromuscular junction chamber can optionally include a support for culturing muscle cells therebetween. The in vitro model can be used, for example, to analyze biological material from a patient or to diagnose a condition.

A first aspect of the invention relates to a method for preparing a three dimensional blood vessel organoid. In a second aspect, the invention is directed to three dimensional human blood vessel organoids obtained or obtainable from the method of the first aspect of the invention. A third aspect of the invention is related to the three dimensional human blood vessel organoids for use in (in vitro) drug screening and / or (in vitro) drug testing; and / or for use in (in vitro) toxicity analysis; and / or for use in (in vitro) bioengineering; and / or for (in vitro) transplant preparation.

Provided herein are engineered human spinal cord organoids and methods of use thereof for development and testing of therapeutic treatment for spinal cord injury.

Provided are methods for culturing a cancer stem cell-derived tissue, which comprise the step of three-dimensionally culturing a cancer stem cell-derived tissue after treating it with a therapeutic agent for diseases. The culture methods of the present disclosure enable the construction of cell clusters analogous to therapeutic agent-resistant tissues which are characteristically seen in tissues of patients who have actually been administered with a therapeutic agent for diseases. The cell clusters of the present disclosure are useful for elucidating the mechanism for acquiring anticancer agent resistance, identifying a therapeutic target therefor, or screening for a therapeutic agent. The preferred disease in the present disclosure is cancer.

The present invention relates to an in vitro testing platform for the study of metabolic liver disease and related therapeutic strategies, composed of an artificial spheroidal microtissue comprising at least hepatocytes and hepatic stellate cells, and at least one type of hepatic inflammatory cells and further medium and reagents capable to establish and simulate different stages of metabolic liver disease and their progression and testing preventive and therapeutic strategies by pharmacological and / or dietary interventions.

There are provided a cell culture device and associated method for preparing an in vitro model of a neuromuscular junction (NMJ). The cell culture device can include a cell culture layer that includes a neuronal cells channel for receiving neuronal cells therein, and a neuromuscular junction chamber in fluid communication with the neuronal cells channel to receive muscle cells therein to enable co-culture of the neuronal cells with the muscle cells and form the NMJ. The neuronal cells channel includes a first portion having a first portion cross-section and a second portion having a second portion cross-section that is smaller than the first portion cross-section and provided downstream of the first portion to retain neuronal cells. The neuromuscular junction chamber can optionally include pillars for culturing muscle cells therebetween. The in vitro model can be used for analysing a biological material from a patient or diagnose a condition, for instance.

The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.